Turmoil and tensions at FDA after dramatic exit of top drug regulator

The dramatic exit of George Tidmarsh from the FDA highlights significant internal dysfunction within the agency, a theme echoed in various sectors where leadership changes often reveal underlying issues. For instance, Brian Kelly's departure from LSU, where he reportedly shifted focus from recruiting to personal interests, mirrors the instability seen at the FDA. Such patterns suggest that leadership transitions can expose deeper organizational challenges, raising questions about the future stability of regulatory bodies and their ability to maintain public trust.